MedKoo Biosciences/Incyclinide/201520/1g

Synonym:CMT-3;CMT3;CMT3;COL3;COL-3;COL3;Incyclinide;4-dedimethylaminosancycline;Chemicallymodifiedtetracycline-3.USbrandname:Metastat.

IUPAC/ChemicalName:(4aS,5aR,12aS)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

InChiKey:ZXFCRFYULUUSDW-OWXODZSWSA-N

InChiCode:InChI=1S/C19H17NO7/c20-18(26)14-11(22)6-9-5-8-4-7-2-1-3-10(21)12(7)15(23)13(8)16(24)19(9,27)17(14)25/h1-3,8-9,21-22,24,27H,4-6H2,(H2,20,26)/t8-,9-,19-/m0/s1

SMILESCode:O=C(C1=C(O)C[C@@](C[C@@]2([H])C(C(C3=C(O)C=CC=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N

TechnicalData

AdditionalInformation

 
 
Informationaboutthisagent
Thechemicallymodifiedtetracycline(CMT)incyclinide(COL-3,CMT-3)hasbeenextensivelystudiedasapotentialnewtherapeuticagentforallergicconditions,inflammatory(i.e.,arthritis,acuterespiratorydistresssyndrome[ARDS],septicshocksyndrome,acneandrosacea),neoplastic(i.e.,Kaposi'ssarcoma,coloncarcinoma,melanoma,prostatecancer)andinfectious(fungal)diseases.ThemostprominentcharacteristicofCMTsistheirlackofantibacterialproperties,accompaniedbyretention,orevenenhancement,ofmetalloproteinase(MMP)inhibition.StudieshavedemonstratedthatincyclinideisamodulatorofMMP-2,MMP-9andserineproteases,aswellascytokinesandinterleukinsthatarecrucialinthedevelopmentofinflammation,angiogenesisandtumOrigenesis.FurThermore,toxicologystudieshavedemonstratedthatincyclinideisrelativelysafe.SeeDrugsFut2007,32(3):209.
 
 

References

1:EdanRA,LuqmaniYA,MasochaW.COL-3,achemicallymodifiedtetracycline,inhibitslipopolysaccharide-inducedmicrogliaactivationandcytokineexpressioninthebrain.PLoSOne.2013;8(2):e57827.doi:10.1371/journal.pone.0057827.Epub2013Feb28.PubMedPMID:23469077;PubMedCentralPMCID:PMC3585197.

2:ParvathySS,MasochaW.MatrixmetalloproteinaseinhibitorCOL-3preventsthedevelopmentofpaclitaxel-inducedhyperalgesiainmice.MedPrincPract.2013;22(1):35-41.doi:10.1159/000341710.Epub2012Aug16.PubMedPMID:22907189.

3:RudekMA,NewP,MikkelsenT,PhuphanichS,AlaviJB,NaborsLB,PiantadosiS,FisherJD,GrossmanSA.PhaseIandpharmacokineticstudyofCOL-3inpatientswithrecurrenthigh-gradegliomas.JNeurooncol.2011Nov;105(2):375-81.doi:10.1007/s11060-011-0602-9.Epub2011May6.PubMedPMID:21547395;PubMedCentralPMCID:PMC3197967.

4:ChuQS,ForouzeshB,SyedS,MitaM,SchwartzG,CooperJ,CurtrightJ,RowinskyEK.AphaseIIandpharmacologicalstudyofthematrixmetalloproteinaseinhibitor(MMPI)COL-3inpatientswithadvancedsofttissuesarcomas.InvestNewDrugs.2007Aug;25(4):359-67.Epub2007Jan20.Erratumin:InvestNewDrugs.2007Aug;25(4):357.Copper,Joshua[correctedtoCooper,Joshua].PubMedPMID:17237909.

5:HalterJM,PavoneLA,SteinbergJM,GattoLA,DiRoccoJ,LandasS,NiemanGF.Chemicallymodifiedtetracycline(COL-3)improvessurvivalifgiven12butnot24hoursaftercecalligationandpuncture.Shock.2006Dec;26(6):587-91.PubMedPMID:17117134.

6:MuirP,ManleyPA,HaoZ.COL-3inhibitionofcollagenfragmentationinrupturedcranialcruciateligamentexplantsfromdogswithstiflearthritis.VetJ.2007Sep;174(2):403-6.Epub2006Sep15.PubMedPMID:16978892.

7:FurlowB.COL-3benefitspatientswithAIDS-relatedKaposi'ssarcoma.LancetOncol.2006May;7(5):368.PubMedPMID:16696161.

8:DezubeBJ,KrownSE,LeeJY,BauerKS,AboulafiaDM.RandomizedphaseIItrialofmatrixmetalloproteinaseinhibitorCOL-3inAIDS-relatedKaposi'ssarcoma:anAIDSMalignancyConsortiumStudy.JClinOncol.2006Mar20;24(9):1389-94.PubMedPMID:16549833.

9:OnodaT,OnoT,DharDK,YamanoiA,NagasueN.Tetracyclineanalogues(doxycyclineandCOL-3)inducecaspase-dependentand-independentapoptosisinhumancoloncancercells.IntJCancer.2006Mar1;118(5):1309-15.PubMedPMID:16152604.

10:LiJ,ZhouS,HuynhH,DuanW,ChanE.AlterationofthepharmacokineticsofCOL-3,amatrixmetalloproteinaseinhibitor,duetoacutegastrointestinaltoxicityofdoxorubicin.PharmRes.2005Nov;22(11):1954-63.Epub2005Aug13.PubMedPMID:16086226.

11:LiJ,ZhouS,HuynhH,ChanE.Significantintestinalexcretion,onesourceofvariABIlityinpharmacokineticsofCOL-3,achemicallymodifiedtetracycline.PharmRes.2005Mar;22(3):397-404.PubMedPMID:15835745.

12:RudekMA,HartkeC,ZabelinaY,ZhaoM,NewP,BakerSD.AsensitivemethodfordeterminationofCOL-3,achemicallymodifiedtetracycline,inhumanplasmausinghigh-performanceliquidchromatographyandultravioletdetection.JPharmBiomedAnal.2005Apr1;37(4):751-6.Epub2004Dec29.PubMedPMID:15797797.

13:SyedS,TakimotoC,HidalgoM,RizzoJ,KuhnJG,HammondLA,SchwartzG,TolcherA,PatnaikA,EckhardtSG,RowinskyEK.AphaseIandpharmacokineticstudyofCol-3(Metastat),anoraltetracyclinederivativewithpotentmatrixmetalloproteinaseandantitumorproperties.ClinCancerRes.2004Oct1;10(19):6512-21.PubMedPMID:15475438.

14:LiJ,HuynhH,ChanE.Reversed-phaseliquidchromatographymethodtodetermineCOL-3,amatrixmetalloproteinaseinhibitor,inBIOLOGicalsamples.JChromatogrBAnalytTechnolBiomedLifeSci.2004Jan25;799(2):311-21.PubMedPMID:14670750.

15:RudekMA,VenitzJ,AndoY,ReedE,PludaJM,FiggWD.FactorsinvolvedinthepharmacokineticsofCOL-3,amatrixmetalloproteinaseinhibitor,inpatientswithrefractorymetastaticcancer:clinicalandexperimentalstudies.JClinPharmacol.2003Oct;43(10):1124-35.PubMedPMID:14517195.

16:ChenYL,HansonGD,WengN,PowalaC,ZerlerB.Quantificationof6-deoxy-6-demethyl-4-dedimethylaminotetracycline(COL-3)inhumanplasmausingliquidchromatographycoupledwithelectrosprayionizationtandemmassspectrometry.JChromatogrBAnalytTechnolBiomedLifeSci.2003Aug25;794(1):77-88.PubMedPMID:12888200.

17:LiJ,HuynhH,ChanE.Evidencefordissolutionrate-limitedabsorptionofCOL-3,amatrixmetalloproteinaseinhibitor,leADIngtotheirregularabsorptionprofileinratsafteroraladmiNISTration.PharmRes.2002Nov;19(11):1655-62.PubMedPMID:12458671.

18:LokeshwarBL,SelzerMG,ZhuBQ,BlockNL,GolubLM.Inhibitionofcellproliferation,invasion,tumorgrowthandmetastasisbyanoralnon-antimicrobialtetracyclineanalog(COL-3)inametastaticprostatecancermodel.IntJCancer.2002Mar10;98(2):297-309.PubMedPMID:11857423.

19:CianfroccaM,CooleyTP,LeeJY,RudekMA,ScaddenDT,RatnerL,PludaJM,FiggWD,KrownSE,DezubeBJ.MatrixmetalloproteinaseinhibitorCOL-3inthetreatmentofAIDS-relatedKaposi'ssarcoma:aphaseIAIDSmalignancyconsortiumstudy.JClinOncol.2002Jan1;20(1):153-9.PubMedPMID:11773164.

20:GhateJV,TurnerML,RudekMA,FiggWD,DahutW,DyerV,PludaJM,ReedE.Drug-inducedlupusassociatedwithCOL-3:reportof3cases.ArchDermatol.2001Apr;137(4):471-4.PubMedPMID:11295928.